FY2025 EPS Estimates for CAPR Increased by Cantor Fitzgerald

Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for Capricor Therapeutics in a report released on Tuesday, April 1st. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will earn ($1.11) per share for the year, up from their previous estimate of ($1.39). Cantor Fitzgerald has a "Overweight" rating and a $30.00 price target on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.21) per share.

Separately, HC Wainwright reiterated a "buy" rating and set a $77.00 target price on shares of Capricor Therapeutics in a research note on Monday, March 17th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $34.50.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock traded down $0.29 during midday trading on Thursday, reaching $8.89. 391,365 shares of the company's stock were exchanged, compared to its average volume of 1,439,341. The stock's 50-day simple moving average is $13.40 and its 200 day simple moving average is $15.19. The firm has a market cap of $406.11 million, a price-to-earnings ratio of -8.38 and a beta of 4.65. Capricor Therapeutics has a 52 week low of $3.52 and a 52 week high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. The firm had revenue of $11.13 million during the quarter, compared to analysts' expectations of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its position in shares of Capricor Therapeutics by 51.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock valued at $1,536,000 after acquiring an additional 37,868 shares during the period. Magnus Financial Group LLC acquired a new stake in Capricor Therapeutics in the 4th quarter worth about $276,000. JPMorgan Chase & Co. boosted its holdings in Capricor Therapeutics by 419.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock valued at $855,000 after purchasing an additional 45,381 shares during the period. State Street Corp increased its holdings in shares of Capricor Therapeutics by 27.8% during the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock worth $7,792,000 after purchasing an additional 111,291 shares during the period. Finally, Swiss National Bank bought a new position in shares of Capricor Therapeutics during the fourth quarter worth approximately $930,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.